Moderna lands $50M to push mRNA Ebola vaccine for Bundibugyo
CEPI pledged over $60 million to accelerate Bundibugyo ebolavirus vaccine development, including up to $50 million to Moderna for preclinical work and early-stage trials of an mRNA BDBV vaccine and to ramp up manufacturing for larger Phase 2/3 testing; other funds go to IAVI and the Oxford/Serum Institute effort. No licensed vaccines exist for Bundibugyo yet, and the current DRC outbreak has about 1,041 cases and 241 deaths as reported by the WHO.